08048036315
Mounjaro 2.5mg INJ affordable tablets to USA -New York,Chicago,Houston|Phoenix Exim|Trusted Exporte

Tirzepatide 2.5 mg Once-Weekly Injection | Type 2 Diabetes Management | Phoenix Exim – Pharmaceutical Exporter from Nagpur, India

Mounjaro 2.5 mg Prefilled Pen contains tirzepatide, a prescription injectable medicine administered subcutaneously once weekly. In the U.S. labeling, Mounjaro is indicated as an adjunct to diet and exercise to improve blood-glucose control in adults and pediatric patients aged 10 years and older with type 2 diabetes mellitus.

Phoenix Exim, based in Nagpur, India, supplies pharmaceutical and healthcare products for international B2B requirements, including markets such as USA, UK, Australia, Singapore, Canada, South Korea and UAE, subject to applicable import, registration, prescription, labeling and regulatory requirements.


1. 🌟 GENERAL INFORMATION

Mounjaro 2.5 mg is a prescription medicine containing Tirzepatide, a dual GIP and GLP-1 receptor agonist.

The 2.5 mg strength is used as the recommended starting dose in the U.S. prescribing information. It is administered once weekly and is designed for treatment initiation rather than ongoing glycemic control. After 4 weeks, the recommended dose is generally increased to 5 mg once weekly under medical supervision.

✦ Product Highlights

  • Prescription injectable medicine

  • Active ingredient: Tirzepatide

  • Starting strength: 2.5 mg

  • Prefilled single-dose pen presentation

  • Subcutaneous administration

  • Once-weekly dosing

  • Used as part of a comprehensive type 2 diabetes treatment plan

  • Manufactured by Eli Lilly and Company for applicable markets


2. πŸ’Ž PRODUCT INFORMATION

Product DetailInformation
BrandMounjaro
Active IngredientTirzepatide
Strength2.5 mg
Dosage FormInjection
DevicePrefilled Single-Dose Pen
RouteSubcutaneous
Dosing FrequencyOnce weekly
Therapeutic ClassGIP/GLP-1 Receptor Agonist
Primary U.S. IndicationType 2 Diabetes Mellitus
OriginMarket-dependent
ExporterPhoenix Exim
Supply BaseNagpur, Maharashtra, India

The U.S. FDA labeling specifies 2.5 mg/0.5 mL for the single-dose pen presentation. Product presentations and regulatory status can differ between countries, so buyers should verify the exact pack and market authorization.


3. 🎯 USES OF MOUNJARO 2.5 MG

πŸ”Ή Type 2 Diabetes Management

Mounjaro is used together with diet and exercise to improve glycemic control in people with type 2 diabetes mellitus.

πŸ”Ή Treatment Initiation

The 2.5 mg dose is primarily a starting dose intended to help patients begin treatment and adjust to tirzepatide. It is not intended as the maintenance dose for glycemic control in the U.S. labeling.

πŸ”Ή Comprehensive Diabetes Care

Mounjaro may be incorporated into an overall diabetes-management plan that includes appropriate nutrition, physical activity, monitoring and other treatments when prescribed.

Important: The approved indications and labeling for tirzepatide vary by country. Use should follow the product's approved local labeling.


4. ⭐ BENEFITS OF MOUNJARO 2.5 MG

When prescribed appropriately, tirzepatide offers several clinically relevant benefits.

βœ” Supports Blood-Glucose Management

Mounjaro helps improve glycemic control when used with diet and exercise in people with type 2 diabetes.

βœ” Dual GIP + GLP-1 Activity

Tirzepatide activates both GIP and GLP-1 receptors, providing its characteristic metabolic effects.

βœ” Convenient Once-Weekly Administration

The medicine is administered once weekly rather than requiring daily injections.

βœ” Prefilled Pen Convenience

The single-dose prefilled pen provides a convenient delivery format for prescribed subcutaneous administration.

βœ” Structured Dose Escalation

Starting at 2.5 mg allows treatment to be initiated at a lower dose before moving to higher doses according to the prescribing schedule and medical supervision.


5. ⚠️ SIDE EFFECTS OF MOUNJARO

Mounjaro can cause adverse reactions, particularly gastrointestinal effects.

Possible side effects include:

  • Nausea

  • Diarrhea

  • Decreased appetite

  • Vomiting

  • Constipation

  • Indigestion/dyspepsia

  • Abdominal pain

These are among the most common adverse reactions identified in the U.S. prescribing information.

Serious adverse reactions can also occur. Patients should review the complete prescribing information and discuss individual risks with their healthcare professional.


6. πŸ”Έ COMMON SIDE EFFECTS

The most common side effects include:

Nausea β€’ Diarrhea β€’ Decreased Appetite β€’ Vomiting β€’ Constipation β€’ Dyspepsia β€’ Abdominal Pain

Gastrointestinal symptoms can be particularly noticeable during dose initiation or escalation. Medical advice should be sought if symptoms are severe, persistent, or concerning.


7. πŸ“‹ HOW TO USE MOUNJARO 2.5 MG

Mounjaro should be used exactly according to the prescribing information and instructions provided by a healthcare professional.

General Administration Information

1. Once Weekly
Mounjaro is administered once per week, at any time of day, with or without meals.

2. Subcutaneous Injection
It is injected under the skin rather than into a vein or muscle.

3. Injection Areas
The abdomen or thigh can be used for self-injection. Another person may administer it into the back of the upper arm. Injection sites should be rotated.

4. Starting Dose
The recommended starting dose is 2.5 mg once weekly for 4 weeks, followed by 5 mg once weekly according to the U.S. prescribing information.

5. Missed Dose
According to the manufacturer's patient information, a missed dose can generally be taken within 4 days (96 hours); if more than 4 days have passed, it should be skipped and the next scheduled dose taken. Two doses should not be taken within 3 days of each other.


8. βš™οΈ HOW DOES MOUNJARO WORK?

Mounjaro contains tirzepatide, which acts as an agonist at both the:

🧬 GIP Receptor

Tirzepatide activates glucose-dependent insulinotropic polypeptide receptors.

🧬 GLP-1 Receptor

It also activates glucagon-like peptide-1 receptors.

πŸ”¬ Combined Metabolic Action

This dual-receptor activity contributes to the medicine's effects on glucose regulation, appetite and gastrointestinal processes.

Tirzepatide also delays gastric emptying, which can affect the absorption of some oral medicines.


9. πŸ›‘οΈ IMPORTANT SAFETY ADVICE

🚨 Thyroid C-Cell Tumor Warning

Mounjaro carries a boxed warning because tirzepatide caused thyroid C-cell tumors in rats. It is unknown whether this applies to humans.

Mounjaro is contraindicated in people with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).

⚠️ Gastrointestinal Effects

Mounjaro can cause gastrointestinal adverse reactions. It is not recommended in patients with severe gastroparesis according to the U.S. prescribing information.

🩺 Pancreatitis

Patients should be evaluated promptly if symptoms suggestive of pancreatitis occur, such as persistent severe abdominal pain.

🟑 Gallbladder Problems

Gallbladder-related events, including cholelithiasis, have occurred during clinical trials.

πŸ‘οΈ Diabetic Retinopathy

Patients with a history of diabetic retinopathy should be appropriately monitored for progression.

πŸ’Š Oral Medicines

Because tirzepatide delays gastric emptying, it may affect the absorption of some oral medicines.

🀰 Pregnancy

Mounjaro may cause fetal harm based on animal studies. Patients who are pregnant or planning pregnancy should discuss treatment with their healthcare professional.

πŸ’Š Oral Contraceptives

The U.S. prescribing information advises individuals using oral contraceptives to switch to a non-oral contraceptive method or add a barrier method for 4 weeks after starting Mounjaro and for 4 weeks after each dose escalation.

πŸ–ŠοΈ Do Not Share the Pen

A Mounjaro KwikPen should never be shared between patients, even if the needle is changed.

❄️ Storage

For the U.S. single-dose pen, storage is generally in a refrigerator at 2Β°C–8Β°C (36Β°F–46Β°F). The pen may be kept at room temperature up to 30Β°C (86Β°F) for up to 21 days under the U.S. instructions. Do not freeze.


10. ❓ FREQUENTLY ASKED QUESTIONS

Q1. What is Mounjaro 2.5 mg?

Mounjaro 2.5 mg is a prescription injectable medicine containing tirzepatide, a dual GIP/GLP-1 receptor agonist.

Q2. What is Mounjaro used for?

In the U.S., Mounjaro is indicated with diet and exercise to improve blood-glucose control in adults and pediatric patients aged 10 years and older with type 2 diabetes.

Q3. Is 2.5 mg the starting dose?

Yes. The U.S. prescribing information recommends 2.5 mg once weekly as the starting dose for 4 weeks, followed by 5 mg once weekly.

Q4. How often is Mounjaro injected?

Mounjaro is administered once weekly.

Q5. Can Mounjaro be taken with food?

Yes. It can be administered at any time of day, with or without meals.

Q6. What are the common side effects?

Common adverse reactions include nausea, diarrhea, decreased appetite, vomiting, constipation, dyspepsia and abdominal pain.

Q7. Can the Mounjaro pen be shared?

No. The pen must not be shared between patients, even if the needle is changed.

Q8. Does Mounjaro require refrigeration?

The U.S. instructions specify refrigeration at 2Β°C–8Β°C. The single-dose pen can be kept at room temperature up to 30Β°C for up to 21 days under those instructions.

Q9. Is Mounjaro a prescription medicine?

Yes. Mounjaro is a prescription medicine.

Q10. Can Mounjaro be exported internationally?

International pharmaceutical requirements differ by destination. Buyers should verify product registration, import authorization, prescription status, cold-chain requirements, labeling, documentation, customs procedures and local regulatory requirements before purchase.


11. πŸ”„ SUBSTITUTE / ALTERNATIVE PRODUCTS

There is no universal one-to-one substitute for Mounjaro. Possible alternatives depend on the patient's diagnosis, treatment goals, medical history and local availability.

Potential Therapeutic Alternatives

  • Other GLP-1 receptor agonists

  • Other GIP/GLP-1 receptor-based therapies

  • Other approved injectable diabetes medicines

  • Oral antidiabetic medicines

  • Insulin therapy where clinically appropriate

Products containing different active ingredients or strengths are not automatically equivalent to Mounjaro 2.5 mg.

A healthcare professional should determine whether an alternative is appropriate.


12. πŸ”Ž SEO KEYWORDS

πŸš€ Primary Product Keywords

  1. Mounjaro 2.5 mg

  2. Mounjaro 2.5 mg Pen

  3. Mounjaro 2.5 mg Injection

  4. Mounjaro Prefilled Pen

  5. Mounjaro 2.5 mg Prefilled Pen

  6. Tirzepatide 2.5 mg Injection

  7. Tirzepatide 2.5 mg Pen

  8. Tirzepatide Prefilled Pen

  9. Mounjaro injection supplier

  10. Tirzepatide injection supplier

🌍 B2B Pharmaceutical Keywords

  1. Mounjaro pharmaceutical supplier India

  2. Mounjaro exporter India

  3. Tirzepatide exporter India

  4. Tirzepatide pharmaceutical supplier

  5. Tirzepatide injection exporter

  6. Mounjaro pen supplier India

  7. Tirzepatide B2B supplier

  8. Diabetes injection supplier India

  9. Pharmaceutical injection exporter India

  10. Injectable medicine exporter Nagpur

🌎 International Market Keywords

  1. Mounjaro supplier USA

  2. Mounjaro supplier UK

  3. Mounjaro supplier Australia

  4. Mounjaro supplier Canada

  5. Mounjaro supplier Singapore

  6. Mounjaro supplier South Korea

  7. Mounjaro supplier UAE

  8. Tirzepatide supplier USA

  9. Tirzepatide supplier UK

  10. Tirzepatide supplier Australia

  11. Tirzepatide supplier Canada

  12. Tirzepatide supplier Singapore

  13. Tirzepatide supplier South Korea

  14. Tirzepatide supplier UAE

  15. Nagpur pharmaceutical exporter

πŸ”₯ Long-Tail SEO Keywords

  1. Mounjaro 2.5 mg prefilled pen pharmaceutical supplier India

  2. Tirzepatide 2.5 mg injection exporter from India

  3. Mounjaro 2.5 mg international pharmaceutical supplier

  4. Tirzepatide prefilled pen B2B supplier India

  5. Mounjaro 2.5 mg pharmaceutical exporter from Nagpur

  6. Tirzepatide injection international supply

  7. Diabetes care injection exporter from India

  8. Tirzepatide 2.5 mg B2B pharmaceutical supplier

  9. Mounjaro prefilled injection supplier India

  10. Tirzepatide injectable medicine exporter India

🏒 Phoenix Exim Keywords

  1. Phoenix Exim pharmaceutical exporter

  2. Phoenix Exim medicine exporter Nagpur

  3. Phoenix Exim injection supplier India

  4. Phoenix Exim Tirzepatide supplier

  5. Phoenix Exim pharmaceutical B2B supplier


🌐 PHOENIX EXIM β€” INTERNATIONAL PHARMACEUTICAL SUPPLY

Mounjaro 2.5 mg Prefilled Pen | Tirzepatide Injection

Phoenix Exim β€” Pharmaceutical & Healthcare Product Exporter from Nagpur, India

🌎 International B2B Supply Markets

πŸ‡ΊπŸ‡Έ USA
πŸ‡¬πŸ‡§ UK
πŸ‡¦πŸ‡Ί Australia
πŸ‡ΈπŸ‡¬ Singapore
πŸ‡¨πŸ‡¦ Canada
πŸ‡°πŸ‡· South Korea
πŸ‡¦πŸ‡ͺ UAE


Aug 10th, 2026 4:15 PM

Keywords